Literature DB >> 8722581

Increased utilization of polyreactive B cells during periods of generalized immune activation.

Y Ishigatsubo1, A D Steinberg, A Krieg, D M Klinman.   

Abstract

This work examines the hypothesis that B cells secreting polyreactive antibodies (antibodies capable of binding to more than one self or foreign antigen) are preferentially utilized during periods of generalized immune stimulation. Four conditions characterized by such stimulation were examined: chronic virus infection, mitogen treatment, autoimmune disease and neonatal repertoire development. In normal adult mice, polyreactive IgM secreting lymphocytes constituted 8-9% of the actively expressed repertoire. Under conditions of generalized immune activation, this frequency increased to 13-19% (p. < .01). Polyreactive IgG secreting B cells, which were present at frequencies of < 0.5% in normal adult mice, were found at freqeuncies of 6-10% in mice with autoimmune disease, chronic virus infection or following mitogen treatment (p. < .001). We postulate that polyreactive lymphocytes are preferentially activated when the immune system is confronted with stimuli inadequately controlled by antigen-specific responses.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8722581     DOI: 10.3109/08916939508995307

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  2 in total

Review 1.  Polyreactive antibodies in adaptive immune responses to viruses.

Authors:  Hugo Mouquet; Michel C Nussenzweig
Journal:  Cell Mol Life Sci       Date:  2011-11-02       Impact factor: 9.261

Review 2.  Autoimmunity, immunodeficiency and mucosal infections: chronic intestinal inflammation as a sensitive indicator of immunoregulatory defects in response to normal luminal microflora.

Authors:  H Tlaskalová-Hogenová; R Stĕpánková; L Tucková; M A Farré; D P Funda; E F Verdú; J Sinkora; T Hudcovic; Z Reháková; B Cukrowska; H Kozáková; L Prokesová
Journal:  Folia Microbiol (Praha)       Date:  1998       Impact factor: 2.099

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.